Biliary Tract Cancer near Bronxville, NY

Care Philosophy: We are committed to delivering the best care and an exceptional patient experience. We are devoted to providing services that are patient-centered and compassionate, and care for you as a person.

Biography: Dr. Usama Ahmed Ali is a colorectal surgeon who has expertise in the whole gamut of colorectal surgery, including minimally invasive and open colorectal surgical procedures, anorectal operations, and colonoscopy. He completed his medical training at Utrecht University in the Netherlands in 2007. He then did colorectal research as a PhD researcher and was a colorectal research fellow at the Cleveland Clinic in 2011 under the guidance of Dr. Pokala Ravi Kiran. He trained in general and colorectal surgery at the University Medical Center Utrecht and the St. Antonius Hospital in The Netherlands after which he worked as a general and colorectal surgeon in Riverieland Ziekenhuis in Tiel until 2022. Dr. Ahmed Ali has an interest in a wide spectrum of colorectal conditions including benign colorectal conditions, diverticular disease, colon and rectal cancer, inflammatory bowel disease, polyposis and anorectal disorders such as hemorrhoids, abscesses and anal fistulas. Dr. Ahmed Ali trained extensively with Dr. Kiran and Dr. James Church. He works collaboratively with Dr. Church on complex fistula disease within the Anal Fistula Center and is part of the Hereditary Cancer and Familial Polyposis Center. He also works closely with Dr. Kiran in the management of various conditions including complex and reoperative colorectal surgery. Dr. Ahmed Ali has a double PhD in medicine, one of which is in the surgical treatment of inflammatory bowel disease. He also has a Masters in Evidence-Based Medicine from Oxford University. He is a Member of Dutch Society for Surgery and Dutch Society for Gastro-intestinal Surgery (2021).

Biography: Dr. Emond is the Vice Chairman of Surgery at Columbia University. He has over 30 years of experience performing liver transplantation and complex liver and biliary surgery in children and adults, including the first living donor liver transplantation (LDLT) in the United States. Dr. Emond has published extensively in this field and was the co-chair of the NIH A2ALL program for 13 years. In collaboration with the department of Medicine at Columbia, Dr. Emond recruited the leadership of the Columbia Center for Translational immunology that created the foundation for translational and clinical research in transplantation tolerance. This will lead the way to inducing transplant tolerance in liver patients with the mixed chimerism strategy. As Director of Transplantation at the Columbia University Medical Center Dr. Emond's activities foster clinical excellence and research across all 11 of the solid organ transplant programs at the Medical Center. In recognition of his national and international leadership in transplantation, Dr. Emond is the past president of the American Society of Transplant Surgeons, the pre-eminent association of a transplant surgery. Contribution to Science Living donor liver transplantation Dr. Emond has spent a substantial portion of his career developing living donor liver transplantation and studying the safety of the procedure in both the donor and recipient. He participated in the first living donor liver transplant in the United States and focused on refining the techniques of performing living donor liver transplants and split liver transplants. He was the national co-chair of the NIH-sponsored Adult-to-Adult Living Donor Liver Transplantation (A2ALL) consortium from 2002 to 2015 to study the safety and outcomes of living donor liver transplants. Hepatic resection/ischemia Dr. Emond developed techniques for surgical resection of liver tumors and studied the effect of ischemia during resection on postoperative liver function. These studies include the outcomes of the extent of hepatectomy, the biochemical response to major hepatectomy and ischemia-reperfusion injury of the liver in rodent models. He has studied the clinical safety of inducing total vascular exclusion to provide a bloodless field during the liver transection. This has applications in both liver cancer and living donor hepatectomies. Hepatocellular carcinoma treatment Dr. Emond has studied many aspects of managing patients with hepatocellular carcinoma. These studies have included characterizing the risk factors for recurrence of disease following transplantation due to comorbidities and tumor characteristics. The research team has also studied the optimal method of preventing tumor growth in patients with HCC on the liver transplant wait list in addition to optimal strategies of liver allocation to optimize outcomes following liver transplantation. These studies have contributed to proposed changes in UNOS exception point allocation for liver transplant candidates with HCC. Pediatric liver transplantation Dr. Emond helped develop the field of pediatric liver transplantation. Contributions to this field include: the use of living donors for pediatric patients; use of auxiliary liver transplants for metabolic diseases; use of partial liver grafts for pediatric patients; and technical modifications that improved outcomes for this patient population. Visit The Center for Liver Disease and Transplantation at columbiasurgery.org/liver